Faron’s business

Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The Company’s lead asset bexmarilimab is being developed for the treatment of blood cancers—currently focusing particularly on myelodysplastic syndrome — and solid tumors.

Faron has a unique business model. The company is a clinical-stage drug developer that operates between the research world and pharmaceutical companies.

Bexmarilimab

Faron’s focus is on the development of its lead asset bexmarilimab. Bexmarilimab is a first-in-class, novel anti-Clever-1-humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments. With a focus on hematological malignancies and solid tumors, our ambition is to bring the promise of immunotherapy to a broader population.

Traumakine

Faron’s investigational intravenous (IV) interferon beta-1a therapy, Traumakine, is being developed in collaboration with the Fred Hutchinson Cancer Research Center in Seattle, Washington, for the development of neurotoxicity related to cytokine release syndrome associated with CAR-T therapy.

The Company’s investigational A0C3 inhibitor targeting VAP-1, a target discovered by Faron’s scientific founders, is undergoing IND-enabling studies.

The information above is disclosed in accordance with Rule 26 of the AIM Rules for Companies.